April 19, 2017
Authored and Edited by Paula E. Miller; Elizabeth D. Ferrill; Jeff T. Watson
In Novartis AG v. Noven Pharmaceuticals Inc., Nos. 16-1678, -1679 (Fed. Cir. Apr. 4, 2017), the Federal Circuit affirmed the PTAB’s decisions finding obvious certain patents that were previously found nonobvious in district court.
Noven filed IPR petitions relating to patents directed to a pharmaceutical composition for the treatment of Alzheimer's disease. Although prior district court decisions found certain claims of those patents nonobvious, the PTAB held that those claims would have been obvious. Novartis appealed, alleging that the PTAB improperly reached a different conclusion than the district court and Federal Circuit in prior litigations.
On appeal, the Federal Circuit noted that the record before the PTAB in this matter differed from that in the prior litigations, explaining that “[t]t is unsurprising that different records may lead to different findings and conclusions.” The Court further explained that the different burdens of proof—“preponderance of the evidence” at the PTAB and “clear and convincing” at the district court—allowed in this case for different conclusions by the PTAB and district court. Although the Federal Circuit stated in a prior decision that the USPTO “ideally should not arrive at a different conclusion” if it faces the same evidence and argument as a district court, the Court explained in this case that this is an aspiration—not a mandate—as Congress authorized a separate review mechanism before the USPTO with its own standard. Accordingly, the Court affirmed the PTAB’s findings of obviousness.
Copyright © 2017 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Conference
Boston Intellectual Property Law Association 4th Annual Symposium
April 10-11, 2024
Boston
Conference
Best Practices in Intellectual Property– A Decade of Dedication to IP Excellence
April 8-9, 2024
Tel Aviv
INCONTESTABLE® Blog
Winning the Battle but Not the War: Disclaimer Requirement Overturned, Section 2(d) Objection Upheld
March 28, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.